Pulmonary hypertension encompasses a range of conditions directly or indirectly leading to
elevated pressures within the pulmonary arteries. Five main groups of pulmonary …

Although cardiovascular diseases (CVDs) are the leading cause of death worldwide, their
pharmacotherapy remains suboptimal. Thus, there is a clear unmet need to develop more …

Background: Activins are novel therapeutic targets in pulmonary arterial hypertension (PAH).
We therefore studied whether key members of the activin pathway could be used as PAH …

Patients with chronic lung diseases, particularly interstitial lung disease and chronic
obstructive pulmonary disease, frequently develop pulmonary hypertension, which results in …

Pulmonary arterial hypertension (PAH) is a complex disease of multifactorial origin. While
registries have demonstrated that women are more susceptible to the disease, females with …

Pulmonary arterial hypertension (PAH) is a severe but treatable form of pre-capillary
pulmonary hypertension caused by pulmonary vascular remodelling. As a result of basic …

Major advances in pulmonary arterial hypertension, pulmonary hypertension (PH)
associated with lung disease, and chronic thromboembolic PH cast new light on the …

Pulmonary arterial hypertension (PAH) is a rare disease characterized by pulmonary
vascular remodeling leading to right heart failure and death. To date, despite the three …

Background In the phase 3 STELLAR trial, sotatercept, an investigational first-in-class activin
signalling inhibitor, demonstrated beneficial effects on 6-min walk distance and additional …

Pulmonary hypertension (PH) is a frequent complication of interstitial lung disease (ILD).
Although PH has mostly been described in idiopathic pulmonary fibrosis, it can manifest in …